Galmed Develops Brain-Penetrating ODF Formulation of SCD1 Inhibitor Aramchol for Parkinson's Disease
Key Insights
Galmed announced an orally dispersible film (ODF) formulation of Aramchol meglumine demonstrating ~150% higher systemic bioavailability and ~300% increase in CNS exposure compared to conventional oral administration.
The ODF formulation addresses dysphagia, which affects up to 80% of Parkinson's patients during disease progression, by dissolving within seconds without water.
Aramchol targets SCD1 (search), a central regulator implicated in α-synuclein (search) aggregation and Lewy body formation, representing a disease-modifying approach distinct from dopaminergic symptomatic therapies.
Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) announced a significant advancement in its Parkinson's disease (search) (PD) program, reporting the development of a novel orally dispersible film (ODF) formulation of its SCD1 (search) inhibitor Aramchol meglumine. The new formulation demonstrated approximately 150% higher systemic bioavailability and a roughly 300% increase in central nervous system (CNS) exposure compared to conventional oral administration, according to data released by the company on July 28, 2026.
The ODF formulation is designed for rapid buccal and sublingual absorption with reduced first-pass hepatic metabolism, maximizing drug exposure within the brain. Aramchol meglumine is currently the only SCD1 (search) inhibitor with an established clinical safety profile and confirmed blood-brain barrier (BBB) penetration.
Addressing Dysphagia in Parkinson's Disease (search)
Beyond enhanced CNS delivery, the proprietary ODF formulation directly targets one of the most prevalent clinical challenges in Parkinson's disease (search): dysphagia. Up to 80% of Parkinson's patients develop swallowing difficulties during disease progression, making conventional tablets and liquid formulations increasingly difficult to administer and contributing to poor treatment adherence. The rapidly dissolving ODF formulation dissolves within seconds without water, eliminating the need to swallow conventional tablets or liquids.
Allen Baharaff, Galmed's Co-founder and CEO, stated: "We believe that combining enhanced CNS exposure to SCD1 (search) inhibition with convenient administration creates an important competitive advantage of Aramchol ODF formulation over conventional therapies."
A Novel Mechanism Targeting Disease Progression
The inhibition of stearoyl-CoA desaturase 1 (SCD1 (search)) represents a novel approach in Parkinson's disease (search) that targets the underlying causes of neurodegeneration. Growing evidence identifies SCD1 as a central regulator of lipid metabolism contributing to α-synuclein (search) aggregation, Lewy body formation, and neuronal dysfunction. Unlike currently approved therapies that primarily improve motor symptoms through dopaminergic replacement, Aramchol targets SCD1-related biological mechanisms associated with disease progression.
Galmed's previously reported in-vitro data demonstrated that Aramchol dose-dependently down-regulated α-synuclein (search) aggregation, with the effect not associated with toxicity.
Strategic Positioning and Market Opportunity
Baharaff further emphasized the program's unique positioning: "In our view, Aramchol's potential for the treatment of PD combines several characteristics that are unique: A well-characterized mechanism of action through SCD1 (search) inhibition, extensive human clinical experience from previous studies with an established safety and tolerability profile, demonstrated preclinical brain penetration, and proprietary ODF technology that significantly enhances CNS drug exposure."
Galmed believes these attributes position Aramchol's PD program as an ideal candidate for co-development and out-licensing, targeting the $6+ billion global Parkinson's therapeutics market where disease-modifying treatment options remain critically limited.
The development builds on Galmed's broader Aramchol platform. In a separate Phase 1 pharmacokinetics study (AM-001) reported in May 2026, the company demonstrated that Aramchol meglumine granules for oral suspension achieved approximately 5-fold greater bioavailability compared to Aramchol free acid tablets. To date, approximately 600 adults have received single or multiple doses of Aramchol free acid across clinical programs, including roughly 240 healthy subjects and 360 patients with metabolic dysfunction-associated steatohepatitis (MASH).